Johnson & Johnson Waits for FDA Ruling on new Diabetes Drug

Before you go, we thought you'd like these...
Before you go close icon

From cutting edge science to the impact of Obamacare, from clinical trial results to FDA decisions, and from Bieber fever to hay fever, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments across the health-care industry and their implications for long-term investors. In this week's edition, the team talks about an exciting drug approval, how computers can help scientists develop new drugs, and stocks that have both soared and crashed. The analysts close with a discussion of companies that they'll be closely following in the coming weeks.

In the segment below, health-care analyst Max Macaluso discusses the upcoming FDA decision regarding Johnson & Johnson's type 2 diabetes drug Invokana, and how the regulatory agency's opinion could be shaped by a previous rejection of a similar drug developed by Bristol-Myers Squibb and AstraZeneca .


Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now

The relevant video segment can be found between 2:39 and 4:15.

The article Johnson & Johnson Waits for FDA Ruling on new Diabetes Drug originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners